Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

“…Outcomes from the model included life expectancy, 10-year medical resource use, incremental cost-effectiveness ratios (ICERs) in $/year of life saved (YLS), and 5-year budget impact. We simulated people with HIV (PWH) in care (mean CD4: 259/<i>μ</i>L, SD 198/<i>μ</i>L) and transmitted cases. …”

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”

Spatial representation of mean annual soil loss increase/decrease derived with the different modeling centers (rows) and time steps (columns) with the SSP5-8.5. by Fabián Santos (8174028)

“…<p>Spatial representation of mean annual soil loss increase/decrease derived with the different modeling centers (rows) and time steps (columns) with the SSP5-8.5.…”

K-fold cross validation accuracy of different models. by Shayla Naznin (13014015)

Subjects:

AQP2 and p-AQP2 abundance. by Sophie Constantin Lütken (689916)

“…Both antibodies reveal specific 29 kDa and 35–50 kDa bands. Data are presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0116501#pone.0116501.t004" target="_blank">Table 4</a>. …”

Fig 5 - by Lingru Ruan (18995544)

AQP1 abundance. by Sophie Constantin Lütken (689916)

“…Immunoblot was reacted with anti-AQP1 antibody and reveals 29 kDa and 35–50 kDa AQP1-bands (<i>A-E</i>). Data are presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0116501#pone.0116501.t009" target="_blank">Table 9</a>. …”

5-HT- induced mitochondrial ROS inhibits <i>P</i>. <i>berghei</i> infection. by Li Gao (131516)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

“…Specifically, compound <b>20g</b> displayed a 3.67-fold decrease of plasma AUC_{(tofacitinib, 0–∞)} and a 9.61-fold increase of colonic AUC_{(tofacitinib, 0–12h)}, compared with tofacitinib at a molar equivalent oral dose. …”

Gsα subunit abundance. by Sophie Constantin Lütken (689916)

Mean scores and 95% CIs according to SARS-CoV-2 infection status and work-related determinants. by A. H. Ayesha Lavell (16734002)

Subjects:

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Fig 9 - by Dennis Ochola (11626912)

Subjects:

Fig 7 - by Dennis Ochola (11626912)

Subjects:

Fig 4 - by Dennis Ochola (11626912)

Subjects:

GSH depletion leads to a strong decrease in SCF-dependent HIF-1α PHD activity in LAD2 cells. by Bernhard F. Gibbs (328262)

Assessment of cell proliferation within the vocal fold muscle following DFATs transplantation. by Ikuo Mikoshiba (9312007)

Subjects:

Naturally occurring antibodies against serum amyloid A reduce IL-6 release from peripheral blood mononuclear cells - Fig 5 by Tadeja Kuret (5059433)

Rap1A knockdown <i>in vitro</i> impairs steady state monolayer integrity and decreases transepithelial electrical resistance. by Erika S. Wittchen (256700)

Role of Ser77 in ACER3 catalytic site. by Jae Kyo Yi (13570063)